Antifungal prophylaxis

Breakthrough Invasive Mould Infections Under Posaconazole Prophylaxis in Patients With Haematologic Malignancies: A Case–Control Study

mycolabadmin

This study examined cases where patients receiving posaconazole to prevent fungal infections still developed serious mould infections despite the medication. Researchers compared 29 patients who developed these breakthrough infections with 46 control patients who did not. They found that over half of patients with breakthrough infections died, compared to only 20% of controls, and that surgical treatment significantly improved survival for certain types of fungal infections.

Invasive Fungal Infections in Orthotopic Heart Transplant Patients: Incidence and Risk Factors in the Modern Era

mycolabadmin

This study examined fungal infections in heart transplant patients at Cleveland Clinic between 2010-2020. Researchers found that about 5% of heart transplant patients developed serious fungal infections, with Candida being the most common culprit. Patients with previous fungal infections, those who needed additional surgeries after transplant, and those requiring life support machines (ECMO) had the highest risk. Heart transplant patients with fungal infections had much worse survival rates, suggesting the need for better prevention strategies using antifungal medications.

Cracks in the Curriculum: The Hidden Deficiencies in Fungal Disease Coverage in Medical Books

mycolabadmin

This study examined how well major medical textbooks cover fungal diseases, which kill millions of people annually. Researchers found that books focused on infectious diseases had much better information about fungal infections than general internal medicine textbooks. Most textbooks failed to adequately cover how to prevent fungal infections and diagnose them correctly, which could lead to delayed treatment and worse patient outcomes.

Antifungal Policy and Practice Across Five Countries: A Qualitative Review

mycolabadmin

This study examined how five countries (Netherlands, Italy, South Korea, China, and India) manage invasive fungal infections through national policies. Researchers found that while all countries have some policies in place, there are significant gaps in diagnosis access, treatment availability, and healthcare professional training. The findings highlight the urgent need for stronger, more comprehensive policies to help patients suffering from serious fungal infections.

Approaches to Invasive Fungal Diseases in Paediatric Cancer Centres: An Analysis of Current Practices and Challenges in Germany, Austria and Switzerland

mycolabadmin

This study examined how 62 children’s cancer hospitals in Germany, Austria and Switzerland manage fungal infections in young cancer patients. Researchers found that hospitals use different methods to prevent and treat these serious infections, with some having special fungal infection experts and others not. The study revealed that larger hospitals tend to have better resources and expertise, while smaller hospitals face challenges like drug interactions and delays in getting test results.

Mycobiome analyses of critically ill COVID-19 patients

mycolabadmin

This study examined fungal infections in severely ill COVID-19 patients treated in intensive care units across Europe. Researchers found that a dangerous mold called Aspergillus fumigatus was more common in patients who died and less common in those treated with azole antifungal drugs. The findings suggest that giving antifungal medications to critically ill COVID-19 patients when they arrive at the hospital might help prevent fungal-related deaths.

Approaches to Invasive Fungal Diseases in Paediatric Cancer Centres: An Analysis of Current Practices and Challenges in Germany, Austria and Switzerland

mycolabadmin

This research examined how pediatric cancer hospitals in Germany, Austria, and Switzerland manage fungal infections, which are a serious risk for children undergoing cancer treatment. The survey found that while most hospitals have infection specialists and antifungal prevention strategies, there are significant differences in how they diagnose and treat these infections. The study identified key challenges like drug interactions and delays in testing, and suggests that better networks between cancer and infection specialists could improve patient care.

Global status and trends of invasive pulmonary aspergillosis: A bibliometric study

mycolabadmin

This study analyzes 24 years of research on invasive pulmonary aspergillosis, a serious fungal infection in immunocompromised patients. Using bibliometric tools, researchers mapped out how the field has evolved, identifying leading countries (USA, Germany, China), key experts like David Denning and Thomas Walsh, and shifting research focus from transplant-related infections to COVID-19-associated cases. The analysis shows the field is rapidly growing with increasing emphasis on rapid diagnostic methods and antifungal therapies.

The Burden of Neonatal Invasive Candidiasis in Low- and Middle-income Countries: A Systematic Review and Meta-analysis

mycolabadmin

This study examined fungal blood infections in newborns across low- and middle-income countries, analyzing data from nearly 11,000 cases. Researchers found these infections occur more frequently and have higher death rates in poorer countries compared to wealthy nations. They identified that most infections are caused by Candida fungus species, and many of these fungi have become resistant to fluconazole, the most commonly used treatment drug.

Enhancing antifungal stewardship: The educational and healthcare benefits of involving pharmacy students in audits

mycolabadmin

This study involved pharmacy students in reviewing fluconazole prescriptions at two Sydney hospitals to improve antifungal medication use. The researchers found that many fluconazole prescriptions were not being used appropriately, and some patients had dangerous drug interactions. The pharmacy students gained valuable real-world experience while helping the hospitals improve their antifungal stewardship practices.

therapeutic action: Antifungal prophylaxis